Introduction to the MoonLake Class Action Lawsuit
- Who is Affected? Purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025.
- The Problem: The MoonLake class action lawsuit alleges the defendant made false and misleading statements driving the stock price artificially up until the truth emerged and the stock plummeted and shareholders who purchased during the relevant time period and suffered a loss are entitle to damages
- Your Action: You may be eligible to recover your losses
- Deadline to Lead: The deadline to apply to be Lead Plaintiff is December 15, 2025
Read to learn the five things every investors must know about the MoonLake class action lawsuit.
1. The Allegations in the MoonLake Class Action Lawsuit
Overview
MoonLake is a clinical stage biotechnology company that focuses on developing therapies for inflammatory skin and joint diseases.
- According to the complaint, MoonLake’s sole drug candidate is sonelokimab (“SLK”), which was developed primarily for the treatment of hidradenitis suppurativa (“HS”).
- Central to SLK’s commercial prospects was its ability to demonstrate efficacy in HS comparable or superior to Union Chimique Belge’s BIMZELX, a U.S. Food & Drug Administration-approved monoclonal antibody for the same indication, the complaint alleges.
False and Misleading Statements
The MoonLake class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- (i) SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F);
- (ii) SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; and
- (iii) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy.
Corrective Disclosure
The MoonLake class action lawsuit alleges that on September 28, 2025, MoonLake announced 16-week results from its Phase 3 VELA program which showed that SLK failed to demonstrate competitive efficacy relative to BIMZELX. On this news, the price of MoonLake stock fell nearly 90%, according to the complaint.
2. How Securities Class Actions Work
- A lead plaintiff files the lawsuit. Usually, an individual or institutional investor who suffered a large financial loss acts as the lead plaintiff, representing the interests of all investors who were harmed. The lawsuit is typically brought by a law firm that specializes in securities litigation.
- The lawsuit proceeds through the court. The case is filed under federal or state securities laws, like the Securities Exchange Act of 1934. The defendant company may file a motion to dismiss the case. If the case proceeds, both sides will enter a lengthy discovery phase to gather evidence.
- Most cases end in a settlement. Rather than going to trial, the company often agrees to pay a sum of money into a common fund to be distributed to the class. The court must approve the fairness of any settlement.
- Claims are administered. If a settlement is reached, a claims administrator is appointed to process claims and distribute funds to eligible investors. The entire process, from filing the complaint to distributing funds, can take several years.
3. The Lead Plaintiff Deadline in the MoonLake Class Action Lawsuit
Lead plaintiff motions for the MoonLake class action lawsuit must be filed with the court no later than December 15, 2025. When a securities class action is filed:
- The person who files the first complaint is required to publish a notice announcing the filing.
- Anyone who wants to be the lead plaintiff on behalf of the class must thereafter file a motion to be appointed as lead plaintiff(s) no later than 60 days after the notice was published.
4. The Eligibility Criteria for Lead Plaintiff Appointment in the MoonLake Class Action Lawsuit
To be eligible for appointment as the lead plaintiff in the MoonLake class action lawsuit, an investor must meet the following criteria:
- Securities Acquisition: The investor must have been purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”).
- Financial Losses: The investor must have suffered financial losses as a direct result of the alleged securities fraud perpetrated by MoonLake and its executives.
- Typicality and Adequacy: The investor’s legal claims must be typical of those asserted on behalf of the class, and they must demonstrate their ability to adequately represent the interests of the entire class through experience, resources, and the absence of conflicts of interest.
It is crucial to note that both domestic and international investors who meet these criteria are eligible to seek appointment as the lead plaintiff in the class action lawsuit, as courts have consistently recognized the rights of non-U.S. investors in securities class actions.
5. Options Available to Shareholders
Shareholders in a securities class action lawsuit can choose to join the class action and receive a portion of the settlement, or they can “opt out” to pursue an independent, direct action against the company.
Options also include selling the right to a recovery, and, in some cases, investors may be able to influence the lawsuit by voting on certain proposals, although the latter is less common and not always an option.
- Join the MoonLake class action lawsuit:
- This is the default option for eligible investors.
- What it is: You are included in the lawsuit and share in the recovery from a settlement.
- Considerations: Recovery can be small (average of about 2% of losses), and payouts can take a long time due to the length of the class action and claims administration process.
- Opt out of the MoonLake class action lawsuit:
- This allows you to pursue a direct, individual claim.
- What it is: You are no longer part of the class and are not bound by the class action’s settlement or outcome.
- Sell the claim:
- It is possible to sell your right to the class action settlement recovery.
- What it is: You can transfer the right to the future payout to a third party in exchange for a smaller, immediate payment.
- Considerations: This can provide immediate liquidity, but you will not receive any money from the class action settlement.
- Vote on proposals (less common):
- In some instances, shareholders may have the opportunity to vote on proposals related to the class action.
- What it is: These are typically “ex ante” proposals before a lawsuit is filed or “ex post” proposals after a lawsuit is filed.
- Considerations: The ability to vote is not guaranteed and depends on the specific circumstances of the lawsuit and the company.
Frequently Asked Questions About the MoonLake Class Action Lawsyut
What initiated the MoonLake class action lawsuit?
The MoonLake class action lawsuit was initiated by investors alleging that Molina Healthcare provided misleading information regarding its financial health and operations, resulting in financial losses.
How can I join the MoonLake class action lawsuit?
If you purchased shares during the class period and suffered a loss, then you are automatically a member of the MoonLake class lawsuit and do not need to do anything at this point unless you are considering moving for lead plaintiff.
What are the potential benefits of a MoonLake class action lawsuit?
Class action lawsuits like the MoonLake class action lawsuit allow individual investors to collectively seek justice and compensation, which might be challenging to pursue individually. They also promote corporate accountability.
How long will the MoonLake class action lawsuit take to resolve?
The duration of class action lawsuits can vary significantly, depending on the complexity of the case, legal strategies, and whether settlements are reached. It could take several months to years to resolve the MoonLake class action lawsuit.
Contact Timothy L. Miles Today About a MoonLake Class Action Lawsuit
The most important thing you need to know is you can call me at no charge if you wish to serve as lead plaintiff of the MoonLake class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected]. (24/7/365).
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com
Facebook Linkedin Pinterest youtube
Visit Our Extensive Investor Hub: Learning for Informed Investors
